














































Activated dendritic cells and monocytes in HIV
immunological nonresponders: HIV-induced
interferon-inducible protein-10 correlates
with low future CD4R recovery
Birgitte Stiksruda,b, Hans C.D. Aassc, Kristina B. Lorvika,d,e,
Thor Uelandf,g, Marius Trøseida,f,h and Anne M. Dyrhol-Riisea,b,i
Objective: To explore monocyte and dendritic cell immune responses, and their associa-
tion with future CD4þ gain in treated HIV patients with suboptimal CD4þ recovery.
Design: A cross-sectional study of HIV-infected, virally suppressed individuals on antire-
troviral therapy for at least 24 months; 41 immunological nonresponders (INRs) (CD4þ cell
count <400 cells/ml) and 26 immunological responders (CD4þ cell count >600 cells/ml).
Ten HIV-infected antiretroviral therapy-naive and 10 HIV-negative healthy persons served
as controls. CD4þ cell counts were registered after median 2.4 and 4.7 years.
Methods: Monocyte, dendritic-cell and T-cell activation and regulatory T cells (Tregs)
were analyzed by flow cytometry. In INR and immunological responder subgroups
matched on age and nadir CD4þ cell count, upregulation of interferon-inducible
protein-10 (IP-10) and indoleamine 2,3-dioxygenase in monocytes and dendritic cells
and cytokines in cell supernatants were measured in vitro in peripheral blood mono-
nuclear cells stimulated with aldrithiol-2-inactivated HIV-1.
Results: The INR group displayed higher spontaneous activation of both monocytes (HLA-
DRþ) and myeloid and plasmacytoid dendritic cells (HLA-DRþ, CD83þ and CD86þ)
compared with immunological responders, and this was associated with increased T-cell
activation (CD38þHLA-DRþ), an effector memory T-cell phenotype and activated Tregs.
The IP-10 response in monocytes after in-vitro HIV stimulation was negatively associated
with prospective CD4þ gain. IP-10, indoleamine 2,3-dioxygenase and cytokines levels
were comparable between the groups, but inversely correlated with activated Tregs in INRs.
Conclusion: HIV-infected individuals with suboptimal immune recovery demonstrated
more activated monocytes and in particular dendritic cells, compared with patients
with acceptable CD4þ gain. A high level of HIV-specific IP-10 expression in monocytes
may be predictive of future CD4þ recovery.
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Introduction
Despite modern antiretroviral therapy (ART) and persis-
tent viral suppression, 15–30% of people living with HIV
(PLWH) do not normalize their CD4þ cell count, denoted
immunological nonresponders (INRs) [1–4]. Low nadir
CD4þ cell count, long duration of HIV-infection before
ART, coinfections such as hepatitis C and older age are well
known factors associated with an incomplete immune
recovery [2,4–6]. INRs have increased chronic immune
activation and inflammation, which probably contribute to
the higher morbidity and mortality seen in this group [7–
11]. Given the substantial proportion of PLWH who still
initiates ART in late disease, INRs will continue to be of
clinical relevance [4,12].
The underlying immunological causes of incomplete
immune recovery are multifactorial. Several studies have
shown a more activated and differentiated T-cell
phenotype [9,13–16] as well as higher percentages of
activated regulatory T cells (aTregs) [10,15,16] in INRs.
We have recently published increased levels of plasma
interferon-inducible protein-10 (IP-10) in an INR
cohort, in which IP-10 and kyurenine/tryptophan ratio,
a measure of indoleamine 2,3-dioxygenase (IDO)
activity, were negatively associated with the CD4þ cell
count after 2 years [16]. IP-10 is mainly produced by
monocytes and myeloid dendritic cells (mDCs) in HIV-
negative persons after in-vitro HIV-1 stimulation [17] and
is also associated with monocyte activation in HIV-
infection [18]. Increased activation of monocytes is
reported even in ART-treated PLWH and is related to
cardiovascular disease and markers of inflammation and
coagulation [19–23]. IDO-activity predicts mortality in
treated HIV-infection [24] and is expressed in mDCs and
plasmacytoid dendritic cells (pDCs) both in simian
immunodeficiency virus (SIV)-infected macaques [25]
and in HIV-negative humans after in vitro stimulation with
inactivated HIV [26,27], or lipopolysaccharide (LPS) in
combination with interferon-gamma (IFN-g) [28].
Dendritic cells serve as a bridgebetween innate and adaptive
immunity, being major drivers of Th1 responses and
persistent IFNa secretion which have antiviral functions,
but also contribute to chronic immune activation.
Furthermore, dendritic cells upregulate IDO and induce
Tregs that could both reduce harmful, general inflammation
and dampen beneficial HIV-specific immune responses
[29–31]. Even virally suppressed PLWH have signs of
dendritic cell dysregulation as some demonstrate subnormal
dendritic cell counts in blood [32–36], weakened pDC
IFNa secretion after exogenous stimuli [36,37] and
impaired mDC induction of Th1 responses [38].
To our knowledge, few studies have investigated
monocytes and dendritic cells in INRs. Increased
proportion of intermediate monocytes [39,40] and lower
absolute pDC count with reduced IFNa production have
been reported in INRs compared with PLWH with
normalized CD4þ cell count [41].
We set out to study activation of monocytes and dendritic
cells in INRs compared with immunological responders,
ART-naive PLWH and healthy controls, and in-vitro
HIV-specific monocyte and dendritic cell responses in
INR and immunological responder subgroups matched
on age and nadir CD4þ cell count. We hypothesized that
INRs had more activated monocytes and dendritic cell
subsets and higher in-vitro production of IP-10, IDO and
cytokines than the immunological responder group that




Forty-one virally suppressed HIV-infected INRs with
CD4þ cell count less than 400 cells/ml and 26
immunological responders with CD4þ cell count more
than 600 cells/ml were recruited between October 2012
and April 2013 as previously reported [16]. Both groups
had received continuous ART for at least 24 months with
HIV-RNA 20 copies/ml or less for the last 18 months.
CD4þ cell counts were obtained from fresh samples and
recorded at baseline and median 2.4 and 4.7 years after
inclusion. The last routine CD4þ cell counts that were
available prior to data analyses of the previous [16] and the
present reports were used. For comparison, 10 ART-
naive individuals with duration of HIV-infection at least
one year and 10 HIV-negative healthy controls, all age
and sex matched, were included. Peripheral blood
mononuclear cells (PBMCs) and EDTA plasma were
sampled from all participants at inclusion, frozen and
stored for later analyses. All participants provided written
informed consent. The study was approved by the
Regional Ethics Committee (1.2007.83 and 2015/629).
Flow cytometry analyses of ex-vivo monocyte
and dendritic cell activation
Flow cytometry analyses were performed on thawed
PBMCs. After 2 h rest, one million (viability >85%)
PBMCs were incubated with Fc block (BD Biosciences,
San Jose, California, USA) prior to staining with surface
markers for 15 min in room temperature. The cells were
fixated in 1% BD CellFIX (BD Biosciences) before
acquisition on BD FACSCanto II (BD Biosciences). The
fluorochrome-conjugated antibodies for the monocyte
and dendritic cell panels are listed in Table S1, http://
links.lww.com/QAD/B453. Results were analyzed with
the FlowJo software version 10.4.1 (Tree Star Inc,
Ashland, Oregon, USA). As staining controls, all
antibodies in the other channels were combined with
concentration matched isotypes for the activation
markers, and fluorescence minus one (FMO) was used
for anti-CD83. The gating strategy is shown in Fig. S1,
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http://links.lww.com/QAD/B453. Monocyte subsets
were defined as CD45þHLA-DRþLineageFixable
Viability and either CD14þþCD16 (classical),
CD14þþCD16þ (intermediate) or CD14þCD16þþ
(nonclassical). Dendritic cells were characterized as
CD45þHLA-DRþLineageFixableViability and fur-
ther subdivided into CD1cþ mDCs, CD141þþ mDCs
or CD303þ pDCs.
Intracellular interferon-inducible protein-10 and
indoleamine 2,3-dioxygenase detection after in-
vitro stimulation with inactivated HIV-1
Owing to the strong association of nadir CD4þ with low
CD4þ recovery, 20 INRs and 20 immunological
responders with comparable age and nadir CD4þ cell
count, and eight age and sex-matched healthy controls
were selected for in-vitro HIV-stimulation analyses (Table
S2, http://links.lww.com/QAD/B453). One million
thawed PBMCs (viability >90%), were cultured for
18 h at 37 8C, 5% CO2 in 200 ml RPMI 1640 (Lonza,
Verviers, Belgium) containing 10% heat-inactivated fetal
calf serum and penicillin/streptomycine/L-glutamine,
with either aldrithiol-2-inactivated (AT-2) HIV-1
(dual-tropic; X4 and R5, lot P4311) at a final
concentration of 500 ng/ml p24 [42], or microvesicles
with equivalent protein concentration (mock) as negative
control [43]. Brefeldin A 1 ml/ml (BD Biosciences) was
added after 6 h. Following stimulation supernatants were
harvested and the cells stained for either monocyte or
dendritic cell surface markers as previously described
(Table S1, http://links.lww.com/QAD/B453), subse-
quently fixated and permeabilized using BD Cytofix/
Cytoperm (BD Biosciences) and stained intracellularly
for IP-10 and IDO (Table S1, http://links.lww.com/
QAD/B453). All IP-10 and IDO responses were
calculated with subtraction of the corresponding mock
stimulated control. For gating strategy see Fig. S2, http://
links.lww.com/QAD/B453.
ELISA and multiplex analyses
Soluble (s)CD163 was analyzed in INRs and immuno-
logical responders from snap frozen EDTA plasma in
duplicate by immunoassay (DY1607; R&D Systems,
Minneapolis, Minnesota, USA) according to the manu-
facturer’s instructions. The intraassay and interassay
coefficients of variation (CV) were less than 10%.
Concentrations of IL-1b, IL-1 receptor antagonist (IL-
1ra), IL-6, IL-10, IL-18, IFNa2, IFNg, tumor necrosis
factor, IP-10 and macrophage inflammatory protein
1beta (MIP-1b)/CCL4 were measured in thawed
supernatants (10 000 g/10 min/4 8C) by nine-plex and
single-plex (Bio-Rad, Oslo, Norway) assays, respectively.
The samples were diluted 1 : 7.5 and 1 : 75 as appropriate,
analyzed with a Luminex IS 100 instrument (Bio-Rad,
Hercules, California, USA) according to instructions
from the manufacturer and run in duplicates. Both
intraassay and interassay CV were less than 10%. All AT-2
HIV virus responses were found by subtracting con-
centrations from the corresponding mock stimulated
sample.
Multiplex and ELISA analyses of other soluble markers in
plasma and flow cytometry phenotyping of T-cell subsets
including Tregs have been previously presented [16], and
are only used in correlation analyses in the current article.
The methods are described in brief in the Supplementary
methods, http://links.lww.com/QAD/B453.
Statistical analyses
Statistical analyses and graphical presentations were
performed by SPSS statistics 25 (IBM Corp., Armonk,
New York, USA) and GraphPad Prism V7.04 software
(GraphPad, San Diego, California, USA) using nonpara-
metric statistics. To reduce the percentage of CV (%CV)
in the flow cytometry experiments caused by small cell
populations, populations consisting of less than 100 cells
were excluded for further analyses of percentages of
activation markers and when less than 50 cells also for
determination of median fluorescence intensity (MFI)
[44]. For comparison between more than two groups
Kruskal–Wallis test followed by Dunn’s post-hoc test
with correction for multiple comparisons were applied.
Mann–Whitney U test was used when analyzing two
groups, Wilcoxon test for paired samples, Fisher’s exact
test or Pearson chi-squared test for categorical variables
and Spearman’s rank correlation for correlation between
parameters. Factors associated with prospective CD4þ
gain were further analyzed with binary logistic regression
adjusting for age, nadir CD4þ cell count and duration
of ART. The outcome variable was dichotomized on
median within the actual patient group. A two-tailed
significance level of 0.05 was set.
Results
Characteristics of the study participants
The baseline characteristics for the INR and immuno-
logical responder cohorts have previously been described
in detail [16]. The ART-naive had median CD4þ cell
count 553 (interquartile range 346–667) cells/ml,
CD4þ/CD8þ ratio comparable with INRs, shorter
duration of HIV infection (P¼ 0.004) and higher nadir
CD4þ cell count (P< 0.001) than both INRs and
immunological responders (Table 1). In the subgroups
matched on age and nadir CD4þ, selected for AT-2 HIV
stimulation assay, the INR group (n¼ 20) had lower viral
load at initiation of continuous ART (P¼ 0.02) and
shorter duration of both viral suppression (P¼ 0.01) and
ART use (P¼ 0.01) compared with the immunological
responder group (n¼ 20) (Table S2, http://links.lww.
com/QAD/B453).
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A median of 4.7 years after inclusion the median CD4þ
gain was 55 (9 to 115) cells/ml among INRs and 37%
had reached a CD4þ cell count above 400 cells/ml.
However, only three persons achieved CD4þ cell count
above 500 cells/ml. The median increase in CD4þ from
2.4 until 4.7 years after inclusion was 18 (29 to 75) cells/
ml and 58% of the INRs increased their CD4þ cell count
in this period. Nevertheless, the CD4þ cell counts
stabilized the last 12 months of follow-up (Fig. S3, http://
links.lww.com/QAD/B453). Duration of continuous
ART and viral suppression, nadir CD4þ and age were all
related to prospective CD4þ cell count and/or CD4þ/
CD8þ ratio (Table S3, http://links.lww.com/QAD/
B453).
Activated monocytes in immunological
nonresponders correlate with T-cell activation
and low CD4R cell counts
We first analyzed the phenotypes of the various monocyte
subsets. In the INR group, the frequency of monocytes
was negatively associated with the CD4þ cell count at
inclusion (r¼0.39, P¼ 0.0012), and the monocytes
constituted a higher fraction of the CD45þ cells within
the INR than in the immunological responder group
(Fig. S3, http://links.lww.com/QAD/B453). The INRs
demonstrated increased MFI of HLA-DR in monocytes
compared with immunological responders (P¼ 0.043),
particularly in the CD14þþCD16þ subset (P¼ 0.013)
(Fig. 1a). The HLA-DR expression correlated with T-cell
activation, an effector memory (EM) T-cell phenotype
and negatively with baseline CD4þ cell count and
CD4þ/CD8þ ratio (r¼0.35, P¼ 0.004) (Table S4,
http://links.lww.com/QAD/B453). Overall, the ART-
naive had the highest CD16 expression in monocytes
(P¼ 0.002) (Fig. S4, http://links.lww.com/QAD/
B453). However, we found no differences between the
HIV groups neither in the distribution of the various
monocyte subsets, nor in the MFI values or frequencies of
cells expressing the activation markers CD142 [tissue
factor (TF)], CD163 or CD11b on these subsets (Fig. S4,
http://links.lww.com/QAD/B453 and Fig. S5, http://
links.lww.com/QAD/B453). Nevertheless, all HIV-pos-
itive groups showed higher MFI of CD142 and lower
MFI and fractions of CD163þ monocytes than healthy
controls (Fig. S5, http://links.lww.com/QAD/B453).
The expression of CD163 or percentages of CD163þ
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Table 1. Characteristics of the study cohort at inclusion.
Total study population INR, n¼41 IR, n¼26 ART-, n¼10 HC, n¼10 P valueM
Age (IQR) 49.9 (41.6–57.9) 45 (39.3–53.8) 50.6 (39.6–59.4) 47.2 (43.5–58.0) NS
Male sex, n (%) 35 (85.4) 18 (69.2) 7 (70) 7 (70) NS
Ethnicity, n (%)
White 29 (70.7) 17 (65.4) 5 (50) 10 (100) NS
Risk group, n (%)
MSM 22 (53.7) 13 (50) 1 (10)MM 0.04
Othera 19 (46.3) 13 (50) 9 (90)MM 0.04
Comorbid diseases, n (%)
Cardiovascular 6 (14.6) 0 (0) 2 (20) NS
Any comorbidityb 21 (51.2) 6 (23.1) 5 (50) NS
CMV IgG pos 41 (100) 25 (96.2) 9 (90) NS
HIV characteristics (IQR)
Years since HIV diagnosis 8.6 (6.4–15.2) 9.2 (7.0–14.1) 3.6 (2.2–6.8)MM,MMM 0.004
Years of continuous ART 5.5 (3.1–6.7) 6.6 (4.4–8.7) NS







Duration of viral suppression
(years)
3.8 (2.0–5.8) 6.1 (4.0–7.6) 0.01
Viral load at inclusion
(copies/ml)
20 20 36 000 (19 750–128 000)MM,MMM <0.001
CD4þ cell count nadir (cells/
ml)
100 (20–157) 180 (120–220) 369 (346–512)MM,MMM,MMMM <0.001
CD4þ cell count at inclusion
(cells/ml)
285 (232–348) 810 (740–864) 553 (346–677)MM,MMMM <0.001
CD8þ cell count at inclusion
(cells/ml)
670 (521–890) 1005 (820–1587) 1257 (973–2491)MM,MMMM <0.001
CD4þ/CD8þ at inclusion 0.43 (0.32–0.57) 0.79 (0.63–0.99) 0.35 (0.25–0.74)MMM,MMMM <0.001
Data are presented as no. (%) of study participants or median IQR values. ART, antiretroviral therapy; ART-, antiretroviral therapy naive HIV-
infected; CMV, cytomegalovirus; HC, healthy control; INR, immunological nonresponder; IQR, interquartile range; IR, immunological responder.
aOther. Heterosexual or unknown. There were no intravenous drug abusers.
bOne or more of the following comorbidities; cardiovascular disease, hypertension, diabetes, renal disease, osteoporosis, chronic obstructive
pulmonary disease, neurodegenerative disease, previous cancer or Mycobacterium tuberculosis infection.
MP values for Kruskal–Wallis test or Pearson Chi-squared test for comparison between multiple groups, Mann–Whitney U test for comparison INR
vs. IR. Significant values are shown in bold.
MMP less than 0.05 for comparison INR vs. ART-. Fisher’s exact test or Dunn’s post-hoc test.
MMMP less than 0.05 for comparison IR vs. ART-. Dunn’s post-hoc test.
MMMMP less than 0.05 for comparison INR vs. IR. Dunn’s post-hoc test.
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Fig. 1. HLA-DR expression in monocyte and dendritic cell subsets in the different cohorts. Parts (a) and (b) show overlay plots of
median fluorescence intensity of HLA-DR in one immunological nonresponder and one immunological responder for various
monocyte and dendritic cell subsets, respectively. The graphs display the differences among healthy control, immunological
responder, immunological nonresponder and antiretroviral therapy-naive groups in the HLA-DR expression in the specific
monocyte (a) and dendritic cell (b) subsets. Kruskal–Wallis test followed by Dunn’s post-hoc test for correction for multiple
comparisons. P<0.05, P< 0.01, P<0.001. Lines indicate median and interquartile range. ART-, antiretroviral therapy naive
HIV-infected; DC, dendritic cells; HC, healthy control; INR, immunological nonresponder; IR, immunological responder; MFI,
median fluorescence intensity.
monocytes were not associated with any inflammation
markers, T-cell activation or Tregs. Furthermore, analysis
of plasma sCD163 revealed no difference between INRs
and immunological responders and no correlation with
cellular CD163 expressed as MFI or frequencies of
CD163þ monocytes.
Dendritic cell activation is increased in
immunological nonresponders and correlates
with T-cell activation and low CD4R cell counts
We then investigated the distribution of pDCs and mDCs
in the various cohorts. The ART-naive had lower fractions
of total dendritic cells compared with both INRs and
healthy controls (P¼ 0.008 and P< 0.001), but there
were no differences between INRs and immunological
responders (Fig. S4, http://links.lww.com/QAD/B453).
Overall, all HIV groups had more activated dendritic cells
than the controls. Still, there was a higher level of dendritic
cell activation in the INR compared with the immuno-
logical responder group (Figs. 1b and 2b–d) with higher
MFI of HLA-DR in the total dendritic cell population,
mainly driven by increased expression in CD1þ mDCs
(P¼ 0.021) (Fig. 1b). Furthermore, the expression of the
maturation marker CD83 in pDCs, the fraction of CD83þ
pDCs and CD83þCD141þ mDCs (Fig. 2b), the expres-
sion of the T-cell costimulatory molecule CD86 in
both mDC subsets (Fig. 2c) and the fraction of
CD83þCD86þCD141þ mDCs (Fig. 2d) were all higher
in INRs than immunological responders. Finally,
activation of pDCs and mDCs correlated strongly with
activated T cells, to a lesser degree with the proportion of
aTregs/resting (r)Tregs, and all the activated dendritic cell
subsets were negatively associated with the baseline CD4þ
cell counts (Table S4, http://links.lww.com/QAD/B453).
There were no relation between dendritic cell activation
and soluble inflammation markers except for a weak
correlation between soluble (s)CD14 and HLA-DR
expression in CD1cþmDC and CD83 in pDCs
(r¼ 0.30, P¼ 0.016, and r¼ 0.32, P¼ 0.011).
HIV-induced upregulation of interferon-
inducible protein-10 and indoleamine 2,3-
dioxygenase in monocytes and myeloid dendritic
cells in vitro are comparable in immunological
nonresponders, immunological responders and
controls
Next, we analyzed the effect of exposure to AT-2 HIV in
vitro upon the various mDC and monocyte subsets in the
INRs, immunological responders and healthy controls.
There was a significant upregulation of both MFI of IDO
and IP-10 and frequencies of IP-10 positive monocyte
and mDC subsets compared with mock-stimulated
samples in all cohorts (Fig. 3), with the exception of
MFI of IDO in CD141þ mDCs, which decreased. The
fraction of IP-10 positive cells increased most in
monocytes, whereas IDO expression was highest in
mDCs. We found no significant differences between the
INR, immunological responder and healthy control
groups neither in frequencies of IP-10þ cells, nor in the
MFI values of IP-10 or IDO in monocytes and mDCs
after AT-2 HIV stimulation (Fig. 3).
High fractions of activated regulatory T cells are
associated with reduced in-vitro HIV-specific
responses in immunological nonresponders
We observed clear cytokine responses after AT-2 HIV
stimulation, although we did not detect any significant
differences between the INRs, immunological respond-
ers and healthy controls (Fig. S6, http://links.lww.com/
QAD/B453). Changes in soluble IP-10 levels correlated
strongly with IP-10 measured by flow cytometry in both
monocytes (DMFI r¼ 0.55, P< 0.001, D% r¼ 0.63,
P¼ 0.001) and mDCs (DMFI r¼ 0.47, P¼ 0.002, D%
r¼ 0.32, P¼ 0.044), suggesting that the IP-10 in the
supernatants could originate from both monocytes and
mDCs. In the INR subgroup the IP-10 expression in
monocytes and/or dendritic cells analyzed by flow
cytometry corresponded to changes in soluble IFNa2,
IL-1ra, IL-18, IFNg and MIP-1b (Table S5, http://
links.lww.com/QAD/B453).
Furthermore, in INRs, the upregulation of both IP-10
and IDO in monocytes and mDCs, as well as the IFNa2,
IL-18 and IFNg responses after exposure to AT-2 HIV,
were strongly inversely correlated with the proportion of
aTregs (Fig. 4a–c). In immunological responders, there
were no such associations.
HIV-specific monocyte interferon-inducible
protein-10 responses are negatively associated
with future CD4R gain
Finally, we aimed to explore markers associated with
future CD4þ gain in the INR group. The increase of
IP-10 expression in monocytes observed after exposure to
AT-2 HIV in vitro, was negatively correlated with the
CD4þ gain seen 2.4 and 4.7 years later (Fig. 4d). In INR
with CD4þ cell count 300 cells/ml or less at baseline this
association was even stronger (r¼0.86, P¼ 0.007) and
there was also a negative correlation between the MFI
IP-10 response and the prospective CD4þ/CD8þ ratio
(r¼0.71, P¼ 0.047). When adjusting for age and nadir
CD4þ, an increase in MFI of IP-10 in monocytes above
median, could still predict a lower CD4þ gain in INRs
after both 2.4 and 4.7 years [2.4 years; odds ratio
(OR)¼ 19.2 (95% confidence interval (CI): 1.1–350.2),
P¼ 0.046 and 4.7 years; OR¼ 21.2 (95% CI: 1.1–
399.6), P¼ 0.041]. Nevertheless, when including dura-
tion of continuous ART in the model, none of the
parameters remained significant.
Discussion
We have explored innate immunity in an INR cohort
compared with ART-treated PLWH with satisfactory
CD4þ recovery, by characterizing monocyte and
1122 AIDS 2019, Vol 33 No 7
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Fig. 2. Dendritic cell activation markers in the various groups. Part (a) illustrates gating strategy of dendritic cell activation
markers based on isotype or fluorescence minus one in total dendritic cells and the different dendritic cell subsets. The plots show
representative examples from one immunological nonresponder and one immunological responder. In parts (b), (c) and (d), the
graphs display both percentage (solid dots) and median fluorescence intensity (open dots) values of the activation markers CD83,
CD86 and the coexpression of CD83 and CD86 in the various dendritic cell subsets for each group. Kruskal–Wallis test followed
by Dunn’s post-hoc test for correction for multiple comparisons. P<0.05, P<0.01, P< 0.001. Lines indicate median and
interquartile range. ART-, antiretroviral therapy naive HIV-infected; DC, dendritic cells; HC, healthy control; INR, immunological
non-responder; IR, immunological responder; MFI, median fluorescence intensity.


















































Fig. 3. Interferon-inducible protein-10 and indoleamine 2,3-dioxygenase responses in monocytes and myeloid dendritic cells
after exposure to aldrithiol-2 inactivated HIV-1 in vitro. Percentages (solid dots) and median fluorescence intensity (open dots) of
interferon-inducible protein-10 in monocytes (a) and myeloid dendritic cells (b) after in-vitro stimulation of peripheral blood
mononuclear cells with either mock (M) or aldrithiol-2 inactivated HIV-1 (H) in healthy controls, immunological responders and
immunological nonresponders. Parts (c) and (d) display indoleamine 2,3-dioxygenase responses in monocytes and myeloid
dendritic cells, respectively. Wilcoxon test for pairwise comparisons between mock and aldrithiol-2 inactivated HIV-1 stimulation.
P< 0.05, P<0.01, P<0.001. Lines indicate median and interquartile range. HC, healthy control; INR, immunological
nonresponder; IR, immunological responder; mDC, myeloid dendritic cell; MFI, median fluorescence intensity.
dendritic cell subsets and responsiveness to in-vitro HIV
stimulation and their associations with T-cell phenotypes.
To our knowledge, this is the first study that presents such
thorough characterization of phenotypes and functional-
ity in innate and adaptive immunity in a group of INRs.
Our main findings can be summarized as follows: first,
INRs demonstrated increased activation of dendritic cells
and monocytes compared with immunological respond-
ers. Second, these changes were associated with T-cell
activation, a shift towards an EM T-cell phenotype
and higher frequency of aTregs. Third, in INRs, the
presence of aTregs was correlated with reduced in-vitro
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Fig. 4. Associations between fraction of activated regulatory T cells and interferon-inducible protein-10, indoleamine
2,3-dioxygenase and cytokine upregulation after exposure to aldrithiol-2 inactivated HIV-1 in vitro and correlation between
interferon-inducible protein-10 responses in monocytes and CD4R recovery after 2 and 4 years. Correlation between percentages of
activated regulatory T cells and indoleamine 2,3-dioxygenase and interferon-inducible protein-10 responses in monocytes (a) and
myeloid dendritic cells (b) and cytokine responses in supernatants (c) after in-vitro stimulation with aldrithiol-2 inactivated HIV-1. (d)
Associations with interferon-inducible protein-10 increase in monocytes after exposure to HIV in vitro and prospective CD4þ gain
after 2 and 4 years. Spearman rank order correlation. The aldrithiol-2 inactivated HIV-1 responses are calculated with subtraction of
the mock stimulated control.INR, immunological nonresponder; IR, immunological responder; aTregs, activated regulatory T cells
(%CD147þþCD25þþ of CD4þ); mDC, myeloid dendritic cell; MFI, median fluorescence intensity.
HIV-specific IDO and cytokine responses, and fourth, a
high HIV-specific increase in IP-10 expression in
monocytes was associated with lower CD4þ recovery
after 2 and 4 years.
mDCs are potent antigen-presenting cells and recognize
diverse pathogens due to their broad expression of Toll-
like receptors (TLRs) [30]. Following TLRs engagement,
mDCs upregulate major histocompatibility complex class
II, the costimulatory molecules CD80 and CD86, and
produce IL-12 which induces Th1 cell responses [30,45].
In our cohorts, INRs showed increased CD86 and HLA-
DR expression in mDCs compared with the immuno-
logical responder group. Activated pDCs are the most
potent producers of IFNa [46] which stimulate a wide
range of immune cells. The maturation marker CD83 was
higher expressed in pDCs in the INR cohort than in
immunological responders and HIV-negative controls.
Furthermore, we found that the activated dendritic cells
were associated with T-cell activation, an EM T-cell
phenotype, as well as the fraction of aTregs/rTregs, and
inversely with the CD4þ cell count. Our results thereby
suggest that activation of dendritic cells is connected to
well known disturbances in the T-cell compartment in both
immune-stimulatory and immune-suppressive directions.
HIV and other viruses can activate pDCs directly
[34,45,47], whereas mDCs seem to be dependent of
exposure to pDC-derived cytokines to mature after
exposure to HIV [34,45]. In HIV-infected individuals
also LPS, other pathogen-derived factors and unmethy-
lated DNA contribute to activation of mDCs and pDCs,
respectively [30,48,49]. We found no correlations
between dendritic cell activation and soluble inflamma-
tion markers in plasma except for a weak correlation with
sCD14. Despite lack of association with LPS, dendritic
cell activation could still be driven by other microbial
products [47,49,50]. Of note, none of the patients had
acute infections, hepatitis C or B viremia, but with one
exception, all were cytomegalovirus (CMV)-positive and
differences in CMV replication and low-level HIV
viremia might be partly responsible for the activation of
dendritic cells [51].
Contrary to a recent report [39], we discovered higher
HLA-DR expression in monocytes in INRs compared
with immunological responders. Bandera et al. studied
frequencies of HLA-DRþ CD14þ cells and as most
monocytes express HLA-DR, such differences could be
more difficult to detect. Variations in definition and
gating strategies of monocytes and different patient
populations can also be a relevant explanation of our
diverging results. As seen for dendritic cells, activated
monocytes correlated inversely with the CD4þ cell count
and were associated with T-cell activation, but not with
soluble inflammation markers linked to non-AIDS
morbidity in ART-treated PLWH. Nevertheless, in line
with two recently published studies, all our HIV groups
showed higher expression of TF than controls, which are
related to coagulation and cardiovascular disease [22,23].
Despite the increased spontaneous ex-vivo activation of
monocytes and dendritic cells seen in INRs, there were
no differences between INRs, immunological responders
and controls in the in-vitro cell upregulation of IP-10 and
IDO or cytokine levels in supernatants. This implies that
innate immunity in INRs preserve their capacity to
respond to the HIV virus. Our data support other studies
reporting similar cytokine production in supernatants in
INRs and immunological responders after exposure to
single-stranded RNA [52], TLR7 or TLR9 [41], yet
IFNa synthesis seemed to be reduced in INRs [41]. Few
had a measurable raise in IFNa2 in our study and the
numbers are thus too low to draw any conclusions. In line
with Simmons et al. [17], we found that monocytes had
the highest fractions of IP-10 positive cells after AT-2 HIV
stimulation. However, in contrast to Boasso et al. [26], we
saw an increase in IDO expression in both monocytes and
mDCs indicating that also monocytes could be an
important source for IDO activity in HIV infection.
Although the increases in cytokines in supernatants and
cellular IP-10 and IDO were similar, the inflammatory
responses seemed to be more closely correlated in INRs
compared with immunological responders. Only in
INRs, the upregulation of IP-10 in monocytes and
mDCs were related to the increase in several supernatant
cytokines. This could imply that IP-10 responses are
accompanied by a more general and possible harmful
immune activation in patients with incomplete immune
recovery. Moreover, we identified a negative association
between the frequency of aTregs and the upregulation of
several cytokines and cellular IDO and IP-10 in INRs,
suggesting that presence of aTregs may suppress HIV-
specific responses in patients with incomplete CD4þ gain.
We recently reported that the level of IP-10 in plasma was
negatively associated with the CD4þ cell count after 2.4
years in the individuals with profoundly impaired immune
reconstitution at inclusion [16]. In the current study, we
found more precisely that the IP-10 response in monocytes
after exposure toHIV in vitrowasnegatively correlated with
the CD4þ gain after median 2.4 and 4.7 years both for the
INR and immunological responder groups, with the
strongest association in individuals with baseline CD4þ cell
count 300 cells/ml less. Type I interferons seem to be
important for IP-10 expression in monocytes after HIV
exposure [17], suggesting that pDCs could play a role in the
IP-10 increase. IP-10 stimulates HIV-replication in vitro
[53]. Moreover, in primary HIV-infection, IP-10 levels are
strongly correlated with HIV RNA and cell-associated
DNA and reported to be a better predictor of disease
progression than the level of viremia [54,55]. In addition,
IP-10 attracts CXCR3þCD4þ T cells which are major
target cells for HIVand also contain the highest amount of
integrated DNA in treated HIV infection [56]. Hence,
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monocytes which respond to HIV with a high IP-10
production could be important in HIV pathogenesis and
potentially unfavorable in the long term also in treated HIV
infection.
Our study has some limitations. We have evaluated HIV-
specific monocyte and dendritic cell responses, but
inclusion of other stimuli such as LPS, flagellin, CpG-
containing DNA and CMV, would have given a more
comprehensive knowledge of factors contributing to
monocyte and dendritic cell activation in INRs.
Furthermore, dendritic cell subsets are rare cell popula-
tions and are sometimes too small for phenotyping and
evaluation of IP-10 and IDO responses. However,
studying PBMCs has an advantage over isolated cell
populations as cytokine responses and in particular IP-10
is dependent of cross-talk between different immune cells
[57]. Finally, about one third of the INRs experienced an
increase in their CD4þ cell count to more than 400 cells/
ml after 4 years, in line with other studies [58]. Some of
these patients were found in the groups selected for in-
vitro AT-2 HIV assays. Although only INRs and
immunological responders with similar age and nadir
CD4þ cell count were selected for this in-vitro assay,
diverse potential for prospective CD4þ recovery in the
INR group could have contributed to the observed lack
of differences in in-vitro responses between INRs and
immunological responders. Thus, for future studies
inclusion criteria with even longer duration of ART
could be preferable.
In conclusion, ART-treated PLWH with an inadequate
immune recovery had a more activated phenotype of
monocytes and in particular dendritic cells, changes that
were related to activation and regulation in the T-cell
compartment. Of note, a high in-vitro HIV-induced IP-
10 expression in monocytes was related to a lower future
CD4þ recovery. As type I interferons are important for
IP-10 expression in monocytes after HIV exposure, an
interplay between viral stimulation of pDCs, activation of
monocytes and subsequent IP-10 expression could be a
relevant pathway involved in inflammation and poor
immune recovery during HIV infection.
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